亚洲部分国家和地区针对罕用药开发的激励措施以及对我国的启示
Incentive measures for orphan drug R&D in several Asian countries and regions and the enlightenment to China
-
摘要: 通过文献分析以及对比研究方法，总结日本、韩国以及中国台湾地区在罕用药开发方面的激励措施。研究发现，日本对罕用药开发的激励力度最大，韩国和中国台湾地区的激励措施相对保守，但均对罕用药的开发起到了促进作用。通过借鉴其政策实施经验，为制定中国罕用药开发的激励措施提出建议。Abstract: Literature review and comparative analysis were employed in this study to summarize the incentivemeasures for facilitating orphan drugs R&D in Japan, South Korea and Taiwan region of China. It was found that the incentive strength in Japan was the greatest among the countries and region above, while those in South Korea and Taiwan region were relatively conservative. Yet all these incentives had promoted the development of orphan drugs and their successful implementation experience have provide suggestions for the establishment of incentive measures for facilitating orphan drugs R&D in China.
-
Keywords:
- orphan drugs /
- incentive measures /
- Japan /
- South Korea /
- Asian
-
-
[1] 张舵,王晓洁.罕见病发病率上升“孤儿药”产业亟待政策支持[N].中国医药报,2013-01-08(7). [2] MHLW.指定年度別の承認取得、開発、指定取消の状況[EB/OL].(2013-07-25)http://www.nibio.go.jp/shinko/s_jyokyo.html. [3] Song PP,Gao JJ,Inagaki Y,et al.Rare diseases,orphan drugs,and their regulation in Asia:Current status and future perspectives[J].Intractable Rare Dis Re,2012,1(1):3-9. [4] 邵建国.亚洲:“孤儿药”的乐土[N].医药经济报,2007-05-14(3). [5] Lee S,Lee JI.Rare disease research and orphan drug development[J].Kor J Clin Pharm,2013, 23(1):8-9. [6] How specific legislation for rare diseases and orphan drugs is changing life for some patients in Taiwan[EB/OL].http://www.orpha.net/actor/EuropaNews/2009/doc/Taiwan.pdf [7] Department of Health,TAIWAN.List of Orphan Drug[EB/OL].[2012-01-31].http://www.doh.gov.tw. [8] Tao Y,Bu YF,Zhang C,et al.Orphan drug management systems in Japan(日本的罕用药管理制度)[J].Chin Pharm J(中国药学杂志),2002,37(6):468-471. [9] Gong SW. Management strategies of improving orphan drugs accessibility in China(促进我国罕见病患者药品可及性的管理策略研究)[D].Wuhan:Huazhong University of Science and Technology,2008. [10] Tang JY,Zhao XY.Contrastive analysis of abroad orphan drug management systems and suggestions for China [J].Chin New Drug J(中国新药杂志),2013, 22(14):1 638-1 642. [11] Xin XX,Guan XD,Chen J,et al.Analysis and comparison of foreign and domestic orphan drug registration policies [J].Chin Pharm J(中国药学杂志),2013,48(15):1 323-1 327. [12] Cheng Y.The Dilemma and outlet of the legal institution of rare disease [J].Hebei Law Sci(河北法学),2011,29(5):10-17. [13] Wu SY, Zhang K. Opportunities and challenges in strategies establishement of rare disease research and prevention in China(中国建立罕见病研究和防治策略的机遇与未来挑战)[J].Shanghai Med Pharm J(上海医药),2011,32(10):502-504. [14] 李天舒.“孤儿药”研发困境等待破局[N].健康报,2011-10-25(5). -
期刊类型引用(10)
1. 严欣，胡蝶，贾瑞瑞，华雅洁，岳远征，王良桂，杨秀莲. 海州常山组培再生体系的建立. 分子植物育种. 2022(04): 1297-1303 . 
百度学术
2. 郝丽亚，李冰洁，王中林，郑新华. 扯根菜化学成分及其保肝活性. 中成药. 2022(09): 2848-2854 . 百度学术
3. 张宇，岑银芝，陈亮，李勇军，孙建博，李林珍. 海州常山茎的化学成分研究(Ⅱ). 中药材. 2022(04): 857-861 . 百度学术
4. 王啸洋，卫柯，陆云阳，佟菲，张艳华，汤海峰. 美花铁线莲茎乙醇提取物正丁醇萃取部位化学成分的提取和鉴定. 环球中医药. 2022(11): 1784-1790 . 百度学术
5. 李林珍，张宇，陈亮，岑银芝，涂杨丽，杨小生，李勇军. 海州常山茎正丁醇部位的化学成分及体外抗肿瘤活性研究. 中国药房. 2022(21): 2578-2583+2589 . 百度学术
6. 刘晓聪，林冬梅，刘敏，张敏，李强，王健，徐露琳，高原，杨健. 番石榴的化学成分及其抗肿瘤与抗真菌活性. 中国中药杂志. 2021(15): 3877-3885 . 百度学术
7. 陈林玉，宋乐园，王云雨，卢梦如，顿彩云，杨青华，毕跃峰. 红小米化学成分与营养成分分析. 食品科学. 2021(18): 218-224 . 百度学术
8. 张吕丽，吴云飞，李祖强，罗蕾. 柄果海桐化学成分研究(Ⅲ). 云南师范大学学报(自然科学版). 2020(02): 55-58 . 百度学术
9. 吴威，宋芷琪，田琨宇，张会永. 豨桐丸的本草考证及组方药物化学成分和药理作用研究进展. 中草药. 2020(17): 4586-4597 . 百度学术
10. 刘璐，张宇，魏茜，李勇军，杨小生，李林珍. 臭梧桐子化学成分研究. 中药材. 2020(07): 1622-1625 . 百度学术
其他类型引用(8)
计量
- 文章访问数: 1124
- HTML全文浏览量: 2
- PDF下载量: 1896
- 被引次数: 18
下载:
